BMS
Top Ten most popular articles on Pharmafile.com this week!
May 17, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics
Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says
May 15, 2019Research and Development AIDS, BMS, Gilead, HIV, Janssen, generic drugs
Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for …
BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme
May 10, 2019Medical Communications, Research and Development BMS, Bristol-Myers Squibb, glioblastoma multiforme, pharma, trial failure
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating …
Top Ten most popular articles on Pharmafile.com this week!
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior
This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …
BMS scores expanded European approval for Sprycel in paediatric leukaemia
February 13, 2019Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma
Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …
Bristol-Myers Squibb withdraws lung cancer combo therapy marketing application
January 25, 2019Medical Communications BMS, Merck, Yervoy, ctla4, lung cancer, opdivo
Bristol-Myers Squibb has been forced to withdraw a marketing application for its combination of Opdivo and Yervoy for lung cancer. …
BMS to acquire Celgene for $74 billion in biggest-ever pharma deal
January 4, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, acquisition, pharma
Starting off 2019 with a bang, Bristol-Myers Squibb has announced its intention to acquire fellow drugmaker Celgene as part of …
Taisho Pharma to buy Bristol-Myers Squibb’s consumer health business in deal worth $1.6 bn
December 19, 2018Business Services BMS, Japan, M&A, MA, Taisho, deal
Japanese company Taisho Pharmaceuticals has offered Bristol-Myers Squibb $1.6 billion for its UPSA consumer health business. With more than a …
CHMP approve Bristol-Myers Squibb’s Sprycel for paediatric patients with Ph+ ALL
December 17, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Sprycel, all
New Jersey-based firm Bristol -Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the …
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund
November 30, 2018Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …
FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival
November 7, 2018Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma
The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …
BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients
October 22, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo
American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …
GSK named third best UK workplace
October 22, 2018Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work
British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …
MSD to launch Keytruda at half US list price in China
September 20, 2018Business Services, Sales and Marketing BMS, China, MSD, global, keytruda, markets, pricing
US pharma giant MSD will offer cutting edge cancer treatment Keytruda to Chinese patients at half the price at what …
Teva names new President, TAPI and Biologics Operations
September 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Novartis, Teva, appointment
Israeli generic drug specialist Teva has announced its appointment of John Nason in a multi-faceted role as President of Teva …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
